Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
World Vitiligo Map
Your guide to the vitiligo community worldwide. Use the selector to filter by patient support groups, specialists, research centers, clinical trial locations, or World Vitiligo Day events.
Directory Information & Disclaimer
This free public directory gathers information from public sources to help connect our global community. Medical professionals and organizations listed are independent and not affiliated with or endorsed by the Vitiligo Research Foundation (VRF), and no fees are accepted for listings.
Because clinics, support groups, and specialists move or update their services over time, some information may occasionally become outdated. As a result, VRF cannot guarantee the complete accuracy or usefulness of listed third-party resources.
Help Us Keep the Map Accurate
Do you need to add a listing, update outdated details, or request a removal? Please reach out to us using the feedback form on our Contact Us page.
Search Map
35 records found for “NCT07533019” · show all
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoResearch Toronto, Toronto, M4W 2N4, Canada
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoSIMa Recherche, Verdun, H4G 2L8, Canada
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoPeking University People's Hospital, Beijing, 100034, China
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoHangzhou Third People's Hospital, Hangzhou, 310009, China
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoThe University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCentrum Badan Klinicznych PI-House sp. z o.o., Gdansk, 80-546, Poland
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoDiamond Clinic, Krakow, 31-559, Poland
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoDermedic Jacek Zdybski, Ostrowiec Świętokrzyski, 27-400, Poland
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoSaguaro Dermatology - Phoenix, Phoenix, Arizona, 85008, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCenter For Dermatology Clinical Research, Inc., Fremont, California, 94538, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoK2 Medical Research - Tampa, Tampa, Florida, 33634, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoStracskin, Portsmouth, New Hampshire, 03801, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoClinical Research Partners, LLC, Richmond, Virginia, 23226, United States
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoThe Centre for Dermatology, Richmond Hill, L4B 1A5, Canada
1-317-615-4559
- A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Phase: PHASE2
Intervention: Drug: LY4005130; Drug: Placebo
Status: Open now
Organizer: Eli Lilly and Company
Trial page: https://vrfoundation.org/trials/ly4005130-antibody-treatment-for-nonsegmental-vitiligoCentrum Medyczne Ginemedica, Wroclaw, 50-414, Poland
1-317-615-4559
FAQOther Questions
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
- Can Ayurveda help with vitiligo?
Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...
- Why Does the IRS Still Show an Old Revocation for VR Foundation?
IRS Status · A Short FAQ The old entry records the past. Publication 78 shows where VR Foundation stands today. Updated August 2026 · EIN 45-2498489 Tax records are rarely elega...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.